EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis

Wytske J Fokkens iD, Joaquim Mullol, David Kennedy, Carl Philpott iD, Veronica Seccia, Robert C Kern, André Coste, Ana R Sousa, Peter H Howarth iD, Victoria S Benson, Bhabita Mayer, Steve W Yancey and 2 more

Allergy · 2023-03 · 78 (3) · 812-821

DOI: 10.1111/all.15434 ↗

At a glance

Randomisierte kontrollierte Studie in Allergy, published online on 2022-07-27. Written by Wytske J Fokkens and 13 co-authors. Institution: Department of Otolaryngology, University of Amsterdam, Amsterdam, Netherlands. Major MEDLINE topics: Nasal Polyps, Sinusitis, Rhinitis. Cited 52 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: GlaxoSmithKline.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often require repeat sinus surgery. Mepolizumab reduced the need for sinus surgery in the SYNAPSE trial; this analysis sought to provide a more in‐depth assessment of surgery endpoints in SYNAPSE.

Methods

SYNAPSE was a double‐blind Phase III trial (NCT03085797) in adults with recurrent, refractory, severe, CRSwNP eligible for repeat sinus surgery despite standard of care treatments and previous surgery. Patients were randomized (1:1) to mepolizumab 100 mg subcutaneously or placebo, plus standard of care, every 4 weeks for 52 weeks. Time to first inclusion on a waiting list for sinus surgery and time to first actual sinus surgery (both up to week 52) were assessed; the latter endpoint was also analyzed post hoc according to time since last sinus surgery before study screening and baseline blood eosinophil count.

Results

Among 407 patients (mepolizumab: 206; placebo: 201), mepolizumab versus placebo reduced the risk of being included on a waiting list for sinus surgery (week 52 Kaplan–Meier probability estimate [95% confidence interval]: 13.9% [9.8%, 19.5%] vs. 28.5% [22.7%, 35.4%]). Mepolizumab versus placebo reduced the risk of sinus surgery irrespective of time (

Subjects

MeSH terms (MEDLINE)

Nasal PolypsSinusitisRhinitisAdultHumansChronic DiseaseAntibodies, Monoclonal, Humanized

Author keywords

chronic rhinosinusitis with nasal polypsmepolizumabrecurrencerefractorysinonasal surgery

Substances

mepolizumabAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Otolaryngology, University of Amsterdam, Amsterdam, Netherlands.
  • Department of Otorhinolaryngology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.
  • Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Norwich Medical School, University of East Anglia, Norwich, UK.
  • Norfolk and Waveney Ear Nose and Throat Service, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK.
  • ENT Unit, Department of Neuroscience, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

ORCID profiles: Wytske J Fokkens, Carl Philpott, Peter H Howarth

Funding

  • GlaxoSmithKline

Cite

APA

Fokkens, W. J., Mullol, J., Kennedy, D., Philpott, C., Seccia, V., Kern, R. C., Coste, A., Sousa, A. R., Howarth, P. H., Benson, V. S., Mayer, B., Yancey, S. W., Chan, R., & Gane, S. B. (2023). Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis. Allergy, 78(3), 812-821. https://doi.org/10.1111/all.15434

Vancouver

Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis. Allergy. 2023;78(3):812-821. doi:10.1111/all.15434

BibTeX
@article{Fokkens2023,
  author = {Fokkens, Wytske J and Mullol, Joaquim and Kennedy, David and Philpott, Carl and Seccia, Veronica and Kern, Robert C and Coste, André and Sousa, Ana R and Howarth, Peter H and Benson, Victoria S and Mayer, Bhabita and Yancey, Steve W and Chan, Robert and Gane, Simon B},
  title = {Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis},
  journal = {Allergy},
  year = {2023},
  volume = {78},
  number = {3},
  pages = {812--821},
  doi = {10.1111/all.15434}
}
Start for free →